WEBULL
News
IONS
86.50
+3.62%
3.02
Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects
Simply Wall St · 2h ago
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts
Benzinga · 1d ago
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Dow Jones · 2d ago
Ionis Pharmaceuticals Price Target Raised to $87.00/Share From $77.00 by Piper Sandler
Dow Jones · 2d ago
Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $87
Benzinga · 2d ago
Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler
TipRanks · 2d ago
IONIS PHARMACEUTICALS INC <IONS.O>: PIPER SANDLER RAISES TARGET PRICE TO $87 FROM $77
Reuters · 2d ago
Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential
Simply Wall St · 2d ago
Top Ionis Pharma Executive Cashes In With Major Stock Move
TipRanks · 3d ago
Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares
Reuters · 3d ago
Ionis Pharmaceuticals EVP Eric Swayze Reports Sale of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals EVP CLO & General Counsel Patrick R. O'Neil Reports Disposal of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals EVP Eugene Schneider Reports Sale of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals CEO Brett P. Monia Reports Disposal of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals CFO Elizabeth L. Hougen Reports Sale of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals EVP Brian Birchler Reports Sale of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares
Reuters · 5d ago
Ionis Pharmaceuticals EVP Chief Business Officer Joseph Baroldi Reports Sale of Common Shares
Reuters · 5d ago
Weekly Report: what happened at IONS last week (0126-0130)?
Weekly Report · 6d ago
Barclays’ Supportive View on Ionis’s RNA Pipeline and Partnerships Might Change The Case For Investing In Ionis Pharmaceuticals (IONS)
Simply Wall St · 02/01 10:31
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.